1334312-52-5Relevant articles and documents
MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV
Nair, Anilkumar G.,Zeng, Qingbei,Selyutin, Oleg,Rosenblum, Stuart B.,Jiang, Yueheng,Yang, De-Yi,Keertikar, Kerry,Zhou, Guowei,Dwyer, Michael,Kim, Seong Heon,Shankar, Bandarpalle,Yu, Wensheng,Tong, Ling,Chen, Lei,Mazzola, Robert,Caldwell, John,Tang, Haiqun,Agrawal, Sony,Liu, Rong,Kong, Rong,Ingravallo, Paul,Xia, Ellen,Zhai, Ying,Nomeir, Amin,Asante-Appiah, Ernest,Kozlowski, Joseph A.
, p. 1954 - 1957 (2018/04/12)
HCV NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays thus making them attractive components for inclusion in an all oral fixed dose combination regimen. Herein, we describe the discovery and characterization of silyl proline-containing HCV NS5A inhibitor MK-8325 with good pan-genotype activity and acceptable pharmacokinetic properties.